InSilico Medicine Announces IND Approval for Rentosertib Inhalation Solution – Key Investor Update

Key Points from the Announcement

• IND Approval Received: InSilico Medicine Cayman TopCo (“InSilico Medicine”) has received Investigational New Drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its self-developed inhaled solution of Rentosertib (ISM001-055) targeting adult idiopathic pulmonary fibrosis (IPF).
• Pipeline Milestone: This marks the 13th program in InSilico Medicine’s AI-driven pipeline to secure IND approval for clinical trials, demonstrating continued progress and momentum in the company’s drug discovery and development efforts.
• Clinical Study Details: The IND approval allows InSilico to initiate a Phase I clinical study. The study will evaluate safety, tolerability, and pharmacokinetic (PK) profiles of Rentosertib inhalation solution, structured in two main parts:
  • A randomized, double-blind, placebo-controlled trial in healthy participants, featuring single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
  • A non-randomized, open-label study in IPF patients receiving multiple doses.
  • Approximately 80 subjects are expected to participate in the trial.
• Drug Profile: Rentosertib (ISM001-055) is a potentially first-in-class small-molecule TNIK inhibitor, discovered and developed using InSilico’s proprietary generative AI platform, Pharma.AI.
• Regulatory Recognition: Rentosertib has significant regulatory milestones:
  • Granted Orphan Drug Designation (ODD) by the U.S. FDA for IPF treatment in February 2023.
  • Included by the CDE in the list of Breakthrough Therapy Designation (BTD) in May 2025.

Important Information for Shareholders and Potential Investors

• Potential Price-Sensitive Impact: The IND approval for Rentosertib’s inhalation solution represents a significant advancement in InSilico Medicine’s clinical pipeline. Regulatory milestones, such as IND clearance and Breakthrough Therapy Designation, can materially affect investor sentiment and share price, especially given the high unmet medical need for IPF and the potential for Rentosertib to be a first-in-class therapy.
• AI-Driven Drug Discovery: The approval underscores the effectiveness and scalability of InSilico’s proprietary AI platform, Pharma.AI, in accelerating drug discovery and development. Success in this area may increase the company’s valuation and attract further investment.
• Clinical and Commercial Potential: With approximately 80 subjects enrolled in the Phase I trial, positive results could lay the groundwork for subsequent pivotal studies and eventual commercialization. The orphan status and breakthrough designation provide potential regulatory and market advantages, such as expedited review and market exclusivity.
• Forward-Looking Risks: Shareholders should note that the company has issued a cautionary statement regarding the uncertainty of forward-looking statements. The data disclosed in this announcement has not been audited or reviewed by external auditors, and there is no guarantee that the anticipated clinical or business milestones will be achieved.

Board and Management Overview

• The Board comprises a mix of executive, non-executive, and independent directors, including Dr. Aleksandrs Zavoronkovs (Chairman, CEO, and CBO), Dr. Feng Ren, Dr. Kan Chen, Dr. Chuen Yan Leung, Dr. Long Shi, Dr. Jingsong Wang, Ms. Denitsa Milanova, and Mr. Roman Kyrychynskyi. This diverse leadership team is instrumental in overseeing the company’s strategic and operational direction.

Summary

InSilico Medicine’s receipt of IND approval for its AI-developed Rentosertib inhalation solution targeting IPF is a pivotal development, reflecting both clinical progress and regulatory validation. The company is positioned to advance its first-in-class TNIK inhibitor through Phase I trials, leveraging orphan drug and breakthrough therapy designations for potential market acceleration. Shareholders should monitor trial outcomes and further regulatory milestones, as these could significantly influence the company’s value and share price.

Disclaimer

The information contained in this article is derived from official company announcements and is intended for informational purposes only. There is no assurance that forward-looking statements or anticipated milestones will materialize. Investors are advised to exercise caution, conduct independent research, and consult professional advisors before making any investment decisions based on this information.

View INSILICO Historical chart here